1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Parabilis Medicines, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOG-001 in Locally Advanced or Metastatic Solid Tumors FOG-001, mFOLFOX-6, Nivolumab - Cancer, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Parabilis Medicines, Inc. | 619 | 2023-05-23 | 2026-10-07 |
Adenomatous Polyposis Coli (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Craniopharyngioma (1) · Desmoid Tumors (1) · Endometrial Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Bevacizumab (1) · Fluorouracil (1) · Leucovorin (1) · Nivolumab (1) · Oxaliplatin (1) · trifluridine tipiracil drug combination (1)
Australia (1) · United States (1)
Benjamin Oshrine (1)